Nanyang Yuexin Biotechnology Co., Ltd. – Trademark Portfolio

Entity Type: 99

Nanyang Yuexin Biotechnology Co., Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include ZHONGMING. The owner is based in Nanyang.

No. 187, diagonally opposite the north gate of the 60th Primary School, Qiliyuan Township, Wolong District

Nanyang 473000 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

ZHONGMING
ZHONGMING
Registered 2026

Trademark Classifications

Nanyang Yuexin Biotechnology Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Nanyang Yuexin Biotechnology Co., Ltd. have?

Nanyang Yuexin Biotechnology Co., Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Nanyang Yuexin Biotechnology Co., Ltd. file in?

Nanyang Yuexin Biotechnology Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Nanyang Yuexin Biotechnology Co., Ltd.'s most well-known trademarks?

Nanyang Yuexin Biotechnology Co., Ltd.'s registered trademark portfolio includes well-known marks such as ZHONGMING. These are among 1 currently registered trademark in the portfolio.

What is Nanyang Yuexin Biotechnology Co., Ltd.'s trademark registration success rate?

Nanyang Yuexin Biotechnology Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.